Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine

Background One promising new Artemisinin-based combination therapies (ACTs) is dihydroartemisinin-piperaquine (DHA-PQ). However, the pharmacokinetics of piperaquine and the relationship between drug levels and clinical efficacy are incompletely characterized, particularly in children. Methods We per...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Zongo, I, Somé, F, Somda, SA, Parikh, S, Rouamba, N, Rosenthal, P, Tarning, J, Lindegardh, N, Nosten, F, Ouédraogo, J
Μορφή: Journal article
Γλώσσα:English
Έκδοση: Public Library of Science 2014
_version_ 1826306048715128832
author Zongo, I
Somé, F
Somda, SA
Parikh, S
Rouamba, N
Rosenthal, P
Tarning, J
Lindegardh, N
Nosten, F
Ouédraogo, J
author_facet Zongo, I
Somé, F
Somda, SA
Parikh, S
Rouamba, N
Rosenthal, P
Tarning, J
Lindegardh, N
Nosten, F
Ouédraogo, J
author_sort Zongo, I
collection OXFORD
description Background One promising new Artemisinin-based combination therapies (ACTs) is dihydroartemisinin-piperaquine (DHA-PQ). However, the pharmacokinetics of piperaquine and the relationship between drug levels and clinical efficacy are incompletely characterized, particularly in children. Methods We performed a single-arm open-label trial in Bobo-Dioulasso, Burkina Faso. A total of 379 participants aged 6 months or more with uncomplicated falciparum malaria were enrolled. Each participant received daily dose of DHA-PQ for three days and followed for 42 days. Parasitological efficacy was analyzed, considering rates of recrudescence and overall recurrence. PK was an exploratory endpoint and a priori, no sample size had been determined. Day 7 capillary and venous plasma concentrations of piperaquine were measured in children aged 2–10 years. Results Of the 379 participants, 365 (96.3%) completed 42 days of follow-up. The median daily dose of PQ was 18.5 mg/kg [6.5–24]. Treatment with DHA-PQ was well tolerated with fever and parasitemia resolution within 48 hours in nearly all children. Recurrent malaria within 42 days of follow-up occurred in 31.3% (10/34) of children less than 2 years old, 16.0% (16/106) of those aged 2–5 years, 9.4% (15/160) of those aged 5–10 years, and none (0/68) of those over 10 years old. After genotyping, 3 of 41 recurrent episodes were recrudescence. An exploratory analysis shows that children with successful treatment outcomes had significantly higher median plasma concentrations of PQ compared to those with recurrent malaria within 42 days after therapy, considering either capillary samples (68 ng/ml [50–85] compared to 48 ng/ml [36–55], p<0.001) or venous samples (42 ng/ml [29–59] compared to 25 ng/ml [19–44], p<0.001). Conclusion DHA-PQ was effective for uncomplicated P. falciparum malaria treatment and offers an alternative to other ACTs. Recurrent malaria was mainly due to new infections after treatment and was correlated with low day 7 PQ concentration in the youngest patients.
first_indexed 2024-03-07T06:42:01Z
format Journal article
id oxford-uuid:f99ee180-9bac-4620-bf9c-2ee9a1b01bfe
institution University of Oxford
language English
last_indexed 2024-03-07T06:42:01Z
publishDate 2014
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:f99ee180-9bac-4620-bf9c-2ee9a1b01bfe2022-03-27T12:59:16ZEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquineJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f99ee180-9bac-4620-bf9c-2ee9a1b01bfeEnglishSymplectic Elements at OxfordPublic Library of Science2014Zongo, ISomé, FSomda, SAParikh, SRouamba, NRosenthal, PTarning, JLindegardh, NNosten, FOuédraogo, JBackground One promising new Artemisinin-based combination therapies (ACTs) is dihydroartemisinin-piperaquine (DHA-PQ). However, the pharmacokinetics of piperaquine and the relationship between drug levels and clinical efficacy are incompletely characterized, particularly in children. Methods We performed a single-arm open-label trial in Bobo-Dioulasso, Burkina Faso. A total of 379 participants aged 6 months or more with uncomplicated falciparum malaria were enrolled. Each participant received daily dose of DHA-PQ for three days and followed for 42 days. Parasitological efficacy was analyzed, considering rates of recrudescence and overall recurrence. PK was an exploratory endpoint and a priori, no sample size had been determined. Day 7 capillary and venous plasma concentrations of piperaquine were measured in children aged 2–10 years. Results Of the 379 participants, 365 (96.3%) completed 42 days of follow-up. The median daily dose of PQ was 18.5 mg/kg [6.5–24]. Treatment with DHA-PQ was well tolerated with fever and parasitemia resolution within 48 hours in nearly all children. Recurrent malaria within 42 days of follow-up occurred in 31.3% (10/34) of children less than 2 years old, 16.0% (16/106) of those aged 2–5 years, 9.4% (15/160) of those aged 5–10 years, and none (0/68) of those over 10 years old. After genotyping, 3 of 41 recurrent episodes were recrudescence. An exploratory analysis shows that children with successful treatment outcomes had significantly higher median plasma concentrations of PQ compared to those with recurrent malaria within 42 days after therapy, considering either capillary samples (68 ng/ml [50–85] compared to 48 ng/ml [36–55], p<0.001) or venous samples (42 ng/ml [29–59] compared to 25 ng/ml [19–44], p<0.001). Conclusion DHA-PQ was effective for uncomplicated P. falciparum malaria treatment and offers an alternative to other ACTs. Recurrent malaria was mainly due to new infections after treatment and was correlated with low day 7 PQ concentration in the youngest patients.
spellingShingle Zongo, I
Somé, F
Somda, SA
Parikh, S
Rouamba, N
Rosenthal, P
Tarning, J
Lindegardh, N
Nosten, F
Ouédraogo, J
Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine
title Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine
title_full Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine
title_fullStr Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine
title_full_unstemmed Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine
title_short Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine
title_sort efficacy and day 7 plasma piperaquine concentrations in african children treated for uncomplicated malaria with dihydroartemisinin piperaquine
work_keys_str_mv AT zongoi efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT somef efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT somdasa efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT parikhs efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT rouamban efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT rosenthalp efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT tarningj efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT lindegardhn efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT nostenf efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine
AT ouedraogoj efficacyandday7plasmapiperaquineconcentrationsinafricanchildrentreatedforuncomplicatedmalariawithdihydroartemisininpiperaquine